real-time news and commentary for investors
Wednesday, Sep 11
Merck's Zostavax needs wider reach
- Despite being approved for people 60 and over for some seven years and for those 50 and older for two years, not enough people are getting Merck's (MRK +0.3%) shingles vaccine Zostavax, according to a study presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
- "This is a potential area where we can do cost avoidance" as shingles costs the health system $1B per year, Bloomberg quotes one Duke University professor as saying.
- Zostavax brought in $651M last year for MRK and has generated $309M in sales this year (as of June).